论文部分内容阅读
应用逆转录病毒构建了IL 12表达载体 ,以研究IL 12基因修饰的肿瘤细胞的肿瘤疫苗作用 ,将其转染EL 4胸腺瘤细胞并研究了该基因导入细胞的抗肿瘤免疫效果。当接种了EL 4 /IL 12转染细胞后 ,在C5 7BL/ 6同系鼠中其基因导入细胞的致瘤性比EL 4 /Wt和EL 4 /Neo组明显减少 (P <0 .0 1) ,在EL 4 /IL 12被排斥后 ,体内试验中实验动物诱发了抗EL 4 /Wt的系统性、保护性免疫 ,51Cr释放测定中 ,获得一个较强的抗EL 4 /Wt和一个较弱的抗同系Lewis肿瘤细胞的CTL活性 ,体内淋巴细胞消除分析的结果提示减少的致瘤性主要依赖于CD4 +,CD8+和NK细胞。这一研究结果提示应用IL 12进行血液肿瘤的治疗是有效的 ,在未来人类癌症的治疗中IL 12亦可有一定的应用前景
The retrovirus was used to construct IL 12 expression vector to study the tumor vaccine effect of IL 12 gene modified tumor cells. The recombinant vaccine was transfected into EL 4 thymoma cells and the antitumor immunity effect of the gene was analyzed. The tumorigenicity of gene-transfected cells in C5 7BL / 6 syngeneic mice after EL 4 / IL 12 transfected cells was significantly reduced compared to EL 4 / Wt and EL 4 / Neo groups (P <0.01) , The systemic and protective immunity against EL 4 / Wt was induced by the experimental animals in vivo after EL 4 / IL 12 was rejected. In the 51Cr release assay, a stronger anti-EL 4 / Wt and a weaker Of anti-homothetic Lewis tumor cells, the results of in vivo lymphocyte depletion assays suggest that the reduced oncogenicity is mainly dependent on CD4 +, CD8 + and NK cells. The findings suggest that the use of IL 12 in the treatment of hematologic malignancies is effective and IL 12 may have potential applications in the future treatment of human cancers